DK149896C - Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf - Google Patents

Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf

Info

Publication number
DK149896C
DK149896C DK241780A DK241780A DK149896C DK 149896 C DK149896 C DK 149896C DK 241780 A DK241780 A DK 241780A DK 241780 A DK241780 A DK 241780A DK 149896 C DK149896 C DK 149896C
Authority
DK
Denmark
Prior art keywords
lrf
analogue
decapeptidamides
nona
preparation
Prior art date
Application number
DK241780A
Other languages
English (en)
Other versions
DK149896B (da
DK241780A (da
Inventor
Jean Edouard Frederic Rivier
Jr Wylie Walker Vale
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of DK241780A publication Critical patent/DK241780A/da
Publication of DK149896B publication Critical patent/DK149896B/da
Application granted granted Critical
Publication of DK149896C publication Critical patent/DK149896C/da

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F11/00—Control or safety arrangements
    • F24F11/30—Control or safety arrangements for purposes related to the operation of the system, e.g. for safety or monitoring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F11/00—Control or safety arrangements
    • F24F11/89—Arrangement or mounting of control or safety devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24F—AIR-CONDITIONING; AIR-HUMIDIFICATION; VENTILATION; USE OF AIR CURRENTS FOR SCREENING
    • F24F2110/00—Control inputs relating to air properties
    • F24F2110/10—Temperature
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Combustion & Propulsion (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK241780A 1979-06-11 1980-06-04 Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf DK149896C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4702679 1979-06-11
US06/047,026 US4244946A (en) 1979-06-11 1979-06-11 Water-soluble peptides affecting gonadal function

Publications (3)

Publication Number Publication Date
DK241780A DK241780A (da) 1980-12-12
DK149896B DK149896B (da) 1986-10-20
DK149896C true DK149896C (da) 1987-04-27

Family

ID=21946676

Family Applications (1)

Application Number Title Priority Date Filing Date
DK241780A DK149896C (da) 1979-06-11 1980-06-04 Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf

Country Status (12)

Country Link
US (1) US4244946A (da)
EP (1) EP0021620B1 (da)
JP (1) JPS565448A (da)
KR (1) KR850001158B1 (da)
AT (1) ATE2617T1 (da)
AU (1) AU533348B2 (da)
CA (1) CA1154758A (da)
DE (1) DE3062118D1 (da)
DK (1) DK149896C (da)
IE (1) IE49822B1 (da)
PH (1) PH15362A (da)
ZA (1) ZA803112B (da)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389613A (en) * 1979-09-21 1995-02-14 Roussel Uclaf Method of treating prostate adenocarcinoma, prostate benign hypertrophia and endometriosis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
WO1982000004A1 (en) * 1980-06-26 1982-01-07 Salk Inst For Biological Studi Contraceptive treatment of male mammals
US4443368A (en) * 1982-11-01 1984-04-17 The Salk Institute For Biological Studies Peptides affecting gonadal function
US4410514A (en) * 1982-12-06 1983-10-18 The Salk Institute For Biological Studies GnRH Agonists
US4489163A (en) 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
EP0518391A1 (en) * 1984-02-23 1992-12-16 The Salk Institute For Biological Studies CRF analogs
US4632979A (en) * 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
US4855407A (en) * 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
HU193093B (en) * 1985-04-16 1987-08-28 Innofinance Process for stimulating sexual activity of birds and domestic mammalians and process for producing spermatocytes for their propagation
HU193607B (en) * 1985-07-18 1987-11-30 Innofinance Altalanos Innovaci Process for production of sexual products applyable for natural or artificial insemination for mammates
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
EP0341935B1 (en) * 1988-05-10 1996-04-10 Alpha-1 Biomedicals, Inc. A solid phase process for synthesizing Thymosin alpha 1
US5169836A (en) * 1988-11-10 1992-12-08 Trustees Of The University Of Penna. Inhibitors of platelet binding
US5328840A (en) * 1989-08-15 1994-07-12 The Research Foundation Of The State University Of New York Method for preparing targeted carrier erythrocytes
US5580957A (en) * 1989-10-30 1996-12-03 The Salk Institute For Biological Studies GnRH analogs
EP0714912B1 (en) 1990-07-17 2002-09-25 The Board Of Regents Of The University Of Oklahoma GMP-140 ligand
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
WO1993003751A1 (en) * 1991-08-26 1993-03-04 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
US7078511B1 (en) 1994-06-23 2006-07-18 Massachusette Institute Of Technology Class BI and CI scavenger receptors
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5843884A (en) * 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US6090784A (en) * 1995-12-01 2000-07-18 Yale University RNA polymerase II peptides and methods of use
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998009984A1 (en) * 1996-09-03 1998-03-12 Yeda Research And Development Co., Ltd. Central nervous system-derived immune privilege factor and uses thereof
AU5243798A (en) 1996-11-06 1998-05-29 Children's Medical Center Corporation Transgenic animal expressing a syndecan in the regions of hypothalamus
EP0937104B1 (en) 1996-11-08 2005-03-23 Oklahoma Medical Research Foundation Endothelium specific expression regulated by epcr control elements
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US20020099040A1 (en) * 1997-09-05 2002-07-25 Monty Krieger Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
EP1056474B1 (en) 1997-11-07 2002-06-12 ConjuChem, Inc. Affinity markers for human serum albumin
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6455499B1 (en) 1999-02-23 2002-09-24 Indiana University Foundation Methods for treating disorders associated with LHRH activity
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
EP1233781A1 (en) * 1999-11-24 2002-08-28 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
WO2002026932A2 (en) 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
US6598784B2 (en) * 2000-12-20 2003-07-29 Meadwestvaco Packaging Syatens, Llc Beverage carton with strap type carrying handle
CA2445947A1 (en) * 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
DE60232733D1 (de) * 2001-08-30 2009-08-06 Sinai School Medicine Alternativ gesplicter zirkulierender gewebefaktor
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20060257428A1 (en) * 2003-08-22 2006-11-16 Harley John B Assays and therapies for latent viral infection
SE0302652D0 (sv) * 2003-10-06 2003-10-06 Amersham Biosciences Ab Attachment of cells to surfaces
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
EP1751175B1 (en) 2004-05-05 2012-07-25 VALORISATION-RECHERCHE, Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2006007368A2 (en) 2004-06-16 2006-01-19 Affinergy, Inc. Biofunctional coatings
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
JP2008542685A (ja) 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CA2641026A1 (en) * 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP2068877A4 (en) 2006-07-19 2011-09-21 Cleveland Clinic Foundation COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
AU2008283802A1 (en) * 2007-07-31 2009-02-05 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US20110014218A1 (en) * 2008-01-25 2011-01-20 University Of North Carolina At Chapel Hill Ixodes scapularis salivary proteins and methods of use for modulation of the alternative complement pathway
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
CA2822442C (en) 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CA2912635A1 (en) 2013-05-24 2014-11-27 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating marfan syndrome and related disorders
US9133241B2 (en) 2013-10-11 2015-09-15 Tarix Pharmaceuticals Ltd. Peptide compositions
CN105828831A (zh) 2013-10-11 2016-08-03 塔瑞克斯制药有限公司 新型肽组合物
EP3077048B1 (en) 2013-12-07 2019-07-17 Case Western Reserve University Compositions and methods of treating thrombosis
JP6673837B2 (ja) 2014-02-13 2020-03-25 アーチ キャンサー セラピューティクス，インク 白血球動員をブロックするペプチドおよび使用方法
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
EP3677285B1 (en) 2014-08-04 2023-12-13 Case Western Reserve University Targeting peptides for detecting prostate cancer
US10716827B2 (en) 2015-05-20 2020-07-21 Syracuse University Compositions and methods for enhancing peptide stability against protease digestion
US20180154007A1 (en) 2015-05-20 2018-06-07 Syracuse University Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist
IL305285A (en) 2015-08-11 2023-10-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
WO2017066552A1 (en) 2015-10-14 2017-04-20 Tarix Pharmaceuticals Ltd. Methods and compositions for the treatment of epidermolysis bullosa
WO2021183863A1 (en) 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
DE2649146A1 (de) * 1975-10-29 1977-05-12 Parke Davis & Co Nonapeptide
JPS5257170A (en) * 1975-10-29 1977-05-11 Parke Davis & Co Novel octapeptide compound and preparation thereof
US4034082A (en) * 1976-03-01 1977-07-05 Abbott Laboratories Method to prevent reproduction in warm-blooded female animals with nonapeptides
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
AU5866380A (en) 1980-12-18
EP0021620A1 (en) 1981-01-07
KR850001158B1 (ko) 1985-08-16
PH15362A (en) 1982-12-10
US4244946A (en) 1981-01-13
DK149896B (da) 1986-10-20
DK241780A (da) 1980-12-12
DE3062118D1 (en) 1983-03-31
AU533348B2 (en) 1983-11-17
EP0021620B1 (en) 1983-02-23
IE49822B1 (en) 1985-12-25
JPH0132838B2 (da) 1989-07-10
ZA803112B (en) 1981-05-27
JPS565448A (en) 1981-01-20
IE801091L (en) 1980-12-11
KR830002687A (ko) 1983-05-30
ATE2617T1 (de) 1983-03-15
CA1154758A (en) 1983-10-04

Similar Documents

Publication Publication Date Title
DK149896C (da) Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf
DK523579A (da) Fremgangsmaade til fremstilling af aminosyrederivater
DK372479A (da) Fremgangsmaade til fremstilling af aminosyrederivater
DK173883D0 (da) Substituerede 8-phenylxanthiner
AR215596A1 (es) Composicion para estirilizar anteras machos en planta y/o disminuir el crecimiento vegetativo
SE427029B (sv) Forfarande for framstellning av acetyleniska aminosyror
IT7949032A0 (it) Procedimento per la preparazione di urochinasi per iniezione
BG36197A3 (en) Method for producing indanylic derivatives
SE7611189L (sv) Nya galeniska beredningar
IT7968549A0 (it) Procedimento per la fabbricazione di cerniere lampo del tipo separabile
ES2038639T3 (es) Procedimiento para la obtencion de alfa-pirrolidonas.
BG38489A3 (en) Method for preparing oxazophosphorine- 6, 4- thiolcalsulphonic acids and their neutral salts
ES2032465T3 (es) Variantes de la hirudina, su utilizacion y su preparacion.
ES480565A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,2 y 1,3 (di-0-n-alquil)glicerilo.
DK51678A (da) Fremgangsmaade til fremstilling af 4"-substituerede aminoderivater af oleandomycin
AU541334B2 (en) Lrf analogue peptides
IT1058772B (it) Procedimento per la preparazione dell ossido di gallio
BG32718A3 (en) Method for obtaininh of derivatives of 4"- deoxy- 4"- aminoeritromizine- a
IT7951108A0 (it) Procedimento per la preparazione di cloridrati di amminoacidi e biclori drati di diamminoacidi
JPS52128394A (en) Novel adenine derivatives and plant jormone containing the same
JPS535124A (en) Organoxilicon composition
IT1206985B (it) Amminoalchilguanidine sostituite eprocedimento per la loro preparazione
BG31501A3 (en) Method for obtaining of 3- arjl- isoxazol- 5- il- benzene carbonic acid and its salts
DK70676A (da) Pyrimidin-(2)-yl-thionophosphorsyreestere fremgangsmade til deres fremstilling samt deres anvendelse som insecticider og acaricider
IT1168146B (it) Derivati del piridazino (4,5-b) chinossalin-5,10-biossido, procedimento per prepararli e composizioni che li contengono

Legal Events

Date Code Title Description
PUP Patent expired